VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed international life sciences industry…
The Netherlands: VarmX appoints Glasspool as CEO
…
…






